Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Kopetz Discusses Triplet Therapy for BRAF-Mutant CRC

May 25th 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses triplet therapy for patients with BRAF-mutant colorectal cancer

Dr. Bekaii-Saab on the Use of Regorafenib in Patients With mCRC

May 24th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

Atezolizumab, Cobimetinib Combo Falls Short in Phase III mCRC Trial

May 10th 2018

Combination therapy with the PD-L1 inhibitor atezolizumab and the MEK inhibitor cobimetinib failed to improve overall survival versus regorafenib in previously treated patients with locally advanced or metastatic colorectal cancer, according to topline findings from the phase III IMblaze370 study.

Marshall Highlights Durable Benefits of Pembrolizumab in GI Cancers

May 3rd 2018

Immunotherapy has arrived in the gastrointestinal cancer landscape, and while not all patients will benefit from these agents, those who do are likely to have long-lasting responses, explained John L. Marshall, MD.

Dr. Atreya on Questions Remaining With Tumor Sidedness in CRC

April 25th 2018

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses questions regarding sidedness in colorectal cancer.

Dr. Kopetz Discusses the Treatment of BRAF-Mutant CRC

April 21st 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with BRAF-mutant colorectal cancer.

Dr. Bhoola on Enhanced Recovery After Surgery in Gynecologic Cancer

April 12th 2018

Snehal Bhoola, MD, assistant professor, Mercer University School of Medicine, associate professor, University of Arizona, Arizona Oncology, discusses enhanced recovery after surgery (ERAS) in gynecologic malignancies.

Dr. Van Loon Discusses the Management of Rectal Cancer

April 10th 2018

Katherine Van Loon, MD, gastrointestinal cancer specialist, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the management of rectal cancer.

Neoadjuvant, Nonoperative Regimens Being Investigated in Rectal Cancer

April 10th 2018

Katherine Van Loon, MD, MPH, discusses the emerging use of neoadjuvant therapy and nonoperative approaches for patients with locally advanced rectal cancer.

Dr. Bekaii-Saab Discusses the Next Steps With Regorafenib in CRC

April 3rd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the next steps following for regorafenib (Stivarga) in colorectal cancer (CRC).

Precision Medicine Impact Grows in GI Cancer Paradigm

March 30th 2018

Bert H. O’Neil, MD, discusses the role of molecular testing throughout GI cancers and highlights the current and developing treatment landscape for patients with colorectal cancer.

Expert Sheds Light on Recent Advances in mCRC

March 29th 2018

Shubham Pant, MD, shares his insight on the future direction of the treatment landscape of colorectal cancer.

Dr. O'Neil Discusses the Current Treatment of Patients With CRC

March 28th 2018

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the current treatment of patients with colorectal cancer.

Dr. Pant on the Future of mCRC Treatment

March 28th 2018

Shubham Pant, MD, associate medical director of the Clinical & Translational Research Center, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing efforts in metastatic colorectal cancer (mCRC) and his hope for the future treatment landscape.

FDA Grants Nivolumab/Ipilimumab Priority Review for MSI-H/dMMR Colorectal Cancer

March 27th 2018

The FDA has granted a priority review to a supplemental biologics license application for nivolumab plus ipilimumab for the treatment of adult patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Immunotherapy, Sidedness Strategies Enhancing mCRC Treatment

March 23rd 2018

Chloe E. Atreya, MD, PhD, discusses the latest treatment advances in mCRC, including tumor sidedness and emerging immunotherapy strategies.

Dr. Van Loon on the PROSPECT Trial

March 21st 2018

Katherine Van Loon, MD, gastrointestinal cancer specialist, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the design of the multicenter PROSPECT trial.

Dr. Overman on the Impact of Nivolumab in mCRC

March 21st 2018

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the impact of nivolumab (Opdivo) on the treatment of patients with metastatic colorectal cancer (mCRC).

Atezolizumab, Cobimetinib Combo Active in mCRC

March 19th 2018

Atezolizumab in combination with cobimetinib induced a 31% disease control rate in patients with heavily-pretreated metastatic colorectal cancer.

Venook Highlights Impact of IDEA Trial in Colon Cancer

March 19th 2018

Alan P. Venook, MD, discusses the significance of the findings of the international IDEA study investigating doses of FOLFOX for patients with colon cancer.